![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 29, 22331-22338, July 21, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, November 30, 1999, and in revised form, March 21, 2000
The signaling pathway by which insulin stimulates
insulin secretion and increases in intracellular free
Ca2+ concentration ([Ca2+]i) in
isolated mouse pancreatic Insulin secreted by pancreatic Several recent studies have indicated that Some of the physiological consequences of insulin receptor activation
at The potential in vivo significance of positive autocrine
feedback on insulin secretion and synthesis was revealed in experiments in which the gene for the The evidence so far has established that insulin activates the insulin
receptor and that this effect results in enhanced insulin synthesis and
insulin secretion. Derangement in this process leads to impaired
insulin secretion similar to that seen in type 2 diabetes. Such results
suggest a potential link between the symptoms of insulin resistance and
impaired insulin secretion found in type 2 diabetes. Given the
potential significance of autocrine activation of insulin secretion and
[Ca2+]i changes, we have investigated some of the
important elements that couple an insulin stimulus to insulin secretion and [Ca2+]i changes and further characterized the
source and temporal characteristics of the
[Ca2+]i changes.
Materials--
Type XI collagenase, HEPES, thapsigargin,
wortmannin, nifedipine, U73122, U73343, bisindolylmaleimide I, and
bovine insulin were obtained from Sigma and used without further
purification. Fluo-4 acetoxymethylester was from Molecular Probes.
Unless otherwise stated, all chemicals for islet and cell culture were
obtained from Life Technologies, Inc. All other chemicals were from
Fisher unless noted and were of highest purity available.
Isolation and in Vitro Culture of Mouse Culture of IRS-1 (+/ Amperometric Detection of Exocytosis--
Microelectrodes were
constructed of carbon fibers sealed in glass micropipettes and were
polished to a 45° angle and cleaned prior to use (23, 24).
Amperometric measurements were made by positioning microelectrodes ~1
µm from a cell and applying stimulant from a micropipette ~ 30 µm from the cell as described elsewhere (23, 24). All experiments
were performed with cells at 37 °C incubated in pH 7.4 Kreb's
Ringer buffer (KRB) containing 118 mM NaCl, 5.4 mM KCl, 2.4 mM CaCl2, 1.2 mM MgSO4, 1.2 mM
KH2PO4, 3 mM d-glucose,
and 20 mM HEPES. Stimulant solutions (100 nM
insulin, 17 mM glucose, or 200 µM
tolbutamide) were prepared by diluting appropriate stock solutions into
KRB.
Amperometry was performed using a battery to apply potential to a
sodium-saturated calomel reference electrode as described previously
(24). For measurements of 5-hydrotryptamine (5-HT) secretion, dispersed
Confocal Imaging of [Ca2+]i--
All
imaging experiments were performed on a Nikon RCM 8000 laser scanning
confocal microscope, consisting of a Nikon Diaphot 300 inverted
microscope, an argon-ion laser (INNOVA Enterprise 622, Coherent),
associated optics, and mechanical and computer control units. Prior to
imaging experiments, 25-mm coverslips containing adherent cells were
loaded with 1 µM fluo-4 acetoxymethylester in KRB for 30 min at 37 °C.
Dye solution was then replaced with KRB, and coverslips with adherent
cells were placed into a 35-mm coverslip holder for immediate use.
Temperature was maintained at 37 °C on the stage of the microscope
through the use of a microincubator (Medical Systems, Corp., Greenvale,
NY) and temperature controller (Warner Instruments, Hamden, CT).
Experimental buffers were the same composition as those used for
amperometric measurements. Images were collected at 1 Hz (average of 32 frames) through a Nikon 40×, (NA 1.15) water immersion objective and
520 ± 10 nm band pass filter using the 488-nm excitation line of
the laser. Images were stored on an optical disc cartridge (TQ-FH332,
Panasonic) for later analysis.
Image and Data Analysis--
Confocal fluorescent images were
played back from the optical disc cartridge, captured, and analyzed
using Simca image analysis software (C-IMAGING Systems, Cranberry
Township, PA) in combination with an 8-bit frame grabber. Regions of
interest (ROI) consisting of either the entire cell or localized
intracellular regions were drawn by free hand and applied to a series
of images. The average intensity of the ROI was measured as a function
of frame number. Because fluo-4 is a single wavelength dye, its
emission is a function of both [Ca2+ ]i and dye
concentration. [Ca2+ ]i changes were therefore
expressed as F1/F0 ratios where F0 was the fluorescence intensity of the
initial image during the recording (25, 26). Ca2+ response
was analyzed as a percentage of increase compared with basal, and the
amount of insulin secretion was analyzed as spikes per stimulation. All
means are reported as ± 1 S.E. Statistical differences between
means were evaluated using a two-tailed Student's t test.
Thapsigargin, Wortmannin, Nifedipine, U73122, and
Bisindolylmaleimide I Treatments--
For amperometric experiments,
mouse
For the [Ca2+ ]i imaging experiments, cells were
stimulated by 100 µM tolbutamide for 5 s to
establish viability. Cells that responded to tolbutamide were then
stimulated with 100 nM insulin, and temporal changes of
[Ca2+ ]i were monitored by fluo-4 fluorescence.
Treatment with inhibitors was similar as in amperometric measurements.
Before insulin stimulation, a control KRB stimulation was applied to the cell to ensure that Ca2+ changes and insulin secretion
were not due to artifacts associated with the buffer application.
Insulin-stimulated Ca2+ Release from Intracellular
Stores--
We had previously reported that application of insulin to
dispersed
The relatively low success rate for insulin stimulation compared with
tolbutamide stimulation is apparently due to cellular heterogeneity and
the difficulty of detecting the insulin-induced signals. Cells that did
not respond to insulin (n = 48) only gave a 72 ± 11% increase in [Ca2+]i with tolbutamide
stimulation, whereas cells that did have a positive response to insulin
(n = 37) averaged a 215 ± 38% increase in
[Ca2+]i with tolbutamide stimulation. Thus, the
nonresponding cells also had a statistically significant
(p < 0.001) lower Ca2+ response to
tolbutamide. Furthermore, the magnitude of the peak Ca2+
response for insulin stimulation is small, averaging <30% that of the
tolbutamide (Fig. 2E). This small signal means that the insulin responses were more difficult to detect than tolbutamide responses. Thus, some of the cells that were counted as not responding may simply have had small responses that were not detectable. This
conclusion is supported by the fact that the nonresponding cells
consistently yielded lower [Ca2+]i responses to tolbutamide.
In 18 (~50%) of the cells that responded to insulin, the
[Ca2+]i increase appeared initially in the
interior of the cell rather than at the edge of the cell (Fig.
1B). In the remaining cells, the
[Ca2+]i increase was observed simultaneously all
across the cell, suggesting that the temporal resolution of the
measurement was too low to locate the initiation of
[Ca2+]i because of rapid diffusion of the
Ca2+. A plot of the relative intensities
(F1/F0) for the cell
interior and the cytoplasm near the cell membrane is compared in Fig.
1D, which shows a higher [Ca2+]i
increase in the interior region. The observation of larger
[Ca2+]i increase in the cell interior is in
contrast to Ca2+ imaging performed with depolarizing
stimuli, such as glucose, that display higher
[Ca2+]i increases at the edge of the cell because
of Ca2+ entry through L-type Ca2+
channels (27). The apparent localization of the Ca2+
changes observed following application of insulin suggests that the
increase in [Ca2+]i is a result of mobilization
from intracellular Ca2+ stores. This conclusion was further
supported by the observation that the magnitude of
[Ca2+]i changes were unaffected by removing
extracellular Ca2+ from the medium or by including 20 µM nifedipine, a blocker of L-type
voltage-gated Ca2+ channels, in the medium (Fig.
4B). In addition, cells treated with 1 µM
thapsigargin, a potent inhibitor of the SERCA pump that depletes
endoplasmic reticulum (ER) stores of Ca2+, had
significantly lower insulin-induced [Ca2+]i
changes (Figs. 3C and
4B) than control cells. These data suggest that the increase in [Ca2+]i evoked
by insulin is a result of Ca2+ release from intracellular
stores, especially the ER.
Requirement of Intracellular Ca2+ Mobilization for
Insulin-stimulated Exocytosis--
After observing intracellular
Ca2+ mobilization following insulin stimulation, we
investigated the possible requirement of Ca2+ mobilization
on insulin-stimulated exocytosis. Exocytosis was monitored by
amperometrically detecting release of 5-HT that had been allowed to
accumulate in the secretory granules of the Involvement of IRS-1 in Insulin-stimulated Exocytosis and Increases
in [Ca2+]i--
We have previously demonstrated
that insulin-stimulated insulin secretion in Wortmannin Sensitivity of Insulin-stimulated Exocytosis and
Ca2+ Response--
After observing IRS-1 involvement in
insulin stimulation of exocytosis in the Roles of Phospholipase C (PLC) and PKC in Insulin-stimulated
Insulin Secretion--
The activation of PI3-K leads to production of
PIP3, which could activate PLC-
Next, we investigated the effect of PKC inhibition on
insulin-stimulated insulin secretion and [Ca2+]i
changes. As shown in Fig. 4, treatment of cells with the PKC inhibitor
bisindolylmaleimide I completely abolished the insulin-stimulated
insulin secretion but had an insignificant effect on
[Ca2+]i changes evoked by insulin. These data
indicate that activation of PKC is not required for Ca2+
mobilization but is strongly involved in the secretory effect induced
by insulin.
The discovery that The increase in [Ca2+]i evoked by insulin appears
to be mediated by release of Ca2+ from intracellular
Ca2+ stores based on the localization of the increase, the
effects of thapsigargin, and the occurrence of
[Ca2+]i changes in the absence of extracellular
Ca2+. The release of intracellular Ca2+
requires activation of IRS-1/PI3-K; however, the complete biochemical mechanism is not clear. The PLC inhibitor study indicates that Ca2+ release does not result from PIP3
activation of PLC via PI3-K; however, because multiple isoforms of PLC
exist and the inhibitor used may not cross-react with all isoforms
(36), it is not possible to completely rule out a role for any isoform
of PLC in the insulin signaling pathway. One possible explanation of
the increases in [Ca2+]i is due to the inhibition
of SERCA pumps on the ER. IRS-1 has been shown to interact with SERCA
proteins (37), and it has recently been demonstrated that
overexpression of IRS-1 in the clonal An important question is whether the increased
[Ca2+]i evoked by insulin is required for the
detected exocytosis. In our experiments, we found that any treatment
that eliminated the [Ca2+]i increase (IRS-1
knockout, PI3-K inhibition, or thapsigargin treatment) also eliminated
secretion. An important coupling point between
[Ca2+]i increases and exocytosis in We have shown that inhibition of PI3-K blocks both the
[Ca2+]i increase and exocytosis evoked by
insulin. PI3-K may be involved in releasing intracellular
Ca2+ through an interaction with the ER, and the resulting
rise in [Ca2+]i may be sufficient for activating
secretion; however, we cannot rule out that PI3-K has other roles in
activating exocytosis. Several lines of evidence suggest that
phosphorylated products of phosphatidylinositol play critical functions
in the regulation of membrane trafficking along the secretory pathway
(40, 41). PI3-K also forms an essential link between the insulin
receptor and glucose transporter translocation and intracellular
vesicular trafficking (42). In addition, PI3-K has been shown to be
involved in regulated exocytosis in adrenal chromaffin cells by an
interaction with the actin cytoskeleton independent of any effects on
Ca2+ (43). A direct link between PI3-K and the late granule
docking step of regulated exocytosis was also suggested from a recent report that synaptotagmin interacts with PIP2 and
PIP3 in a Ca2+-dependent manner
(44). Thus, the involvement of PI3-K in autocrine activation of insulin
secretion opens up a number of possible routes for secretion regulation
in Fig. 6 presents a summary of the possible
pathways for the effects of insulin on Ca2+ and insulin
secretion within the Our data have identified some important contributors to the observed
activation of insulin secretion and increased
[Ca2+]i evoked by insulin at the *
This work was supported by National Institutes of Health
Grants DK31036 and DK 33201 (to C. R. K.) and DK46960 (to
R. T. K.) and National Institutes of Health National Research
Service Award Fellowship DK-09825-02 (to R. N. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Chemistry, University of Florida, Gainesville, FL 32611. Tel.:
352-392-9839; Fax: 352-392-4582; E-mail: rtkenn@chem.ufl.edu.
Published, JBC Papers in Press, March 11, 2000, DOI 10.1074/jbc.M909647199
The abbreviations used are:
IRS, insulin
receptor substrate;
PI3-K, phosphatidylinositol 3-kinase;
PIP3, phosphatidylinositol 3,4,5-triphosphate;
DMEM, Dulbecco's modified Eagle's medium;
KRB, Kreb's Ringer buffer;
5-HT, 5-hydrotryptamine;
ROI, regions of interest;
SERCA, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase;
ER, endoplasmic reticulum;
PLC, phospholipase C;
PKC, protein kinase
C.
Roles of Insulin Receptor Substrate-1, Phosphatidylinositol
3-Kinase, and Release of Intracellular Ca2+ Stores in
Insulin-stimulated Insulin Secretion in
-Cells*
,
,
,
¶
Department of Chemistry, University of
Florida, Gainesville, Florida 32611-7200 and the § Research
Division, Joslin Diabetes Center and Department of Medicine, Harvard
Medical School, Boston, Massachusetts 02215
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cells and clonal
-cells was
investigated. Application of insulin to single
-cells resulted in
increases in [Ca2+]i that were of lower
magnitude, slower onset, and longer lifetime than that observed with
stimulation with tolbutamide. Furthermore, the increases in
[Ca2+]i originated from interior regions of the
cell rather than from the plasma membrane as with depolarizing stimuli.
The insulin-induced [Ca2+]i changes and insulin
secretion at single
-cells were abolished by treatment with 100 nM wortmannin or 1 µM thapsigargin; however,
they were unaffected by 10 µM U73122, 20 µM
nifedipine, or removal of Ca2+ from the medium.
Insulin-stimulated insulin secretion was also abolished by treatment
with 2 µM bisindolylmaleimide I, but
[Ca2+]i changes were unaffected. In an insulin
receptor substrate-1 gene disrupted
-cell tumor line, insulin did
not evoke either [Ca2+]i changes or insulin
secretion. The data suggest that autocrine-activated increases in
[Ca2+]i are due to release of intracellular
Ca2+ stores, especially the endoplasmic reticulum, mediated
by insulin receptor substrate-1 and phosphatidylinositol 3-kinase.
Autocrine activation of insulin secretion is mediated by the increase
in [Ca2+]i and activation of protein kinase C.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cells is the primary regulator
of serum glucose concentrations in mammals. Although substantial progress has been made in elucidating the mechanisms responsible for
normal regulation of insulin secretion from the
-cell, many aspects
of this process remain unclear. In particular, chemical and
physiological interactions between cells within the islet exert an
important level of control in the physiological regulation of insulin
secretion that is not entirely understood. Both hormonal and neuronal
influences within islets may modulate
-cell activity and insulin
secretion in vitro and in vivo (1-3). Although
such influences have been demonstrated, the existence of significant autocrine effects of insulin on
-cells remained controversial for
many years because a variety of studies yielded conflicting evidence on
the modulation of insulin secretion by insulin in whole islets or
in vivo. Recently, however, a variety of new methods have
been utilized that demonstrate potent and possibly clinically important
autocrine actions of insulin.
-cells express components
of insulin signaling systems including insulin receptors (4-6),
insulin receptor substrates (IRS-1 and
IRS-2)1 (7-9),
phosphatidylinositol 3-kinase (PI3-K) (10, 11), and protein kinase B
(12). Evidence has also been obtained indicating that insulin released
by glucose can activate these components in addition to other proteins
in the cells. Insulin binds to receptors on the surface of
-cells
(4, 13) and activates tyrosine phosphorylation of insulin receptors
(6), insulin receptor substrates (8), and PHAS-I (an inhibitor of mRNA
cap-binding protein) (14). Furthermore, maximal glucose-stimulated
production of phosphatidylinositol 3,4,5-triphosphate
(PIP3), a major product of PI3-K activity, coincides with
the early peak phase insulin secretion in islets and clonal
-cells
(10). Thus, autocrine activation of the
-cell insulin
receptors and several downstream proteins has been demonstrated.
-cells have recently been revealed. Activation of the insulin
signaling pathway in
-cells leads to initiation of insulin synthesis
at both transcriptional and translational levels, increasing the
cellular content of releasable hormone in primary and clonal
-cell
cultures (14-16). In
TC6-F7 cells transfected to overexpress
the insulin receptor, basal and glucose-stimulated insulin secretion
was enhanced compared with kinase negative controls (15). In another
report, clonal cells lacking the IRS-1 protein showed both decreased
insulin content and glucose-stimulated secretion (17). These latter
studies suggest that insulin can exert positive control over synthesis
and/or secretion. Direct evidence for the effects of insulin on insulin
secretion has been obtained by application of exogenous insulin to
isolated
-cells and detecting secretion by amperometry (18). These
data illustrate that insulin evokes insulin secretion mediated by the
insulin receptor and that such positive feedback occurs during glucose
stimulation. This report also showed that insulin could evoke an
increase in intracellular [Ca2+]
([Ca2+]i). A recent study with clonal
-cells demonstrated that overexpression of IRS-1 and insulin
receptor elevated [Ca2+]i levels and enhanced
fractional insulin secretion (19), in good agreement with the studies
on application of exogenous insulin.
-cell insulin receptor was inactivated by
use of the Cre-loxP system (20). Mice lacking the
-cell insulin
receptor had lowered insulin response to glucose and impaired glucose
tolerance, suggesting an important role for autocrine signaling in
insulin secretion and glucose homeostasis in vivo. Further
evidence for the importance of autocrine action was obtained when a
polymorphism in IRS-1 in humans was associated with impaired insulin
secretion and pathology of some forms of type 2 diabetes (21). The
identical polymorphism expressed in clonal
-cells reduced glucose
and sulfonylurea-stimulated insulin secretion.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-Cells--
Islets
were isolated from 20-30 g of CD-1 mice. Briefly, islets were isolated
by ductal injection with collagenase type XI and dispersed into single
cells by shaking in dilute (0.025%) trypsin/EDTA for 8 min at
37 °C. Cells were cultured on 35-mm tissue culture dishes (Nunclon)
or 25-mm glass coverslips at 37 °C, 5% CO2, pH 7.4, in
RPMI 1640 containing 10% fetal bovine serum, 100 units/ml penicillin,
and 100 µg/ml streptomycin and used on days 2-4 following isolation.
) and IRS-1 (
/
) Cells--
Cell lines
expressing the IRS-1 protein and IRS-1-specific knockouts were derived
from breeding wild-type and IRS-1 (
/
) mice with mice expressing the
SV40 T antigen (RIP-Tag) on a
-cell-specific promoter similar to the
procedure used by Efrat et al. (22) to derive
TC3 cells.
Tumors from 12-14-week-old RIP-Tag/IRS-1(+/
) and
RIP-Tag/IRS-1(
/
) mice were manually dissected and placed in DMEM
supplemented with fetal calf serum, penicillin, and streptomycin. The
tumor capsule was disrupted, and the cells were gently dispersed with
forceps. Tumor cells were purified by gravity sedimentation and seeded
in a 48-well plate containing DMEM. IRS-1 (+/
) and IRS(
/
) clonal
cells were grown to approximately 80% confluence and split 1:3 in DMEM
supplemented with 20% fetal bovine serum.
TC3 cells were cultured
in 200-ml tissue culture flasks in DMEM containing 25 mM
d-glucose, 10% fetal bovine serum, 100 units/ml penicillin,
and 100 µg/ml streptomycin at 37 °C, 5% CO2. Cells were passaged with 0.05% trypsin/EDTA at 70% confluence and plated onto 35-mm tissue culture plates (Nunclon) for single cell experiments. Cells were used on days 2-4 following passage.
-cells were incubated in tissue culture medium containing 0.5 mM 5-hydroxytryptophan for 16 h at 37 °C, 5%
CO2, pH 7.4. Cells were used for secretion experiments
immediately after loading. For detection of 5-HT, the potential at the
working electrode was 0.65 V versus sodium-saturated calomel
reference electrode. Data were low pass filtered at 100 Hz and
collected at 500 Hz using a personal computer (Gateway 2000 P5-166)
via a data acquisition board (Axon Instruments, DigiData 1200B). For amperometric data analysis, current spikes were used only if the signal-to-noise ratio was >10.
-cells were stimulated with 100 nM insulin and
exocytosis of 5-HT detected by amperometry to establish viability.
Following successful repetitive stimulation with insulin, 100 nM wortmannin, 1 µM thapsigargin, 20 µM nifedipine, 10 µM U73122, or 2 µM bisindolylmaleimide I was added to the buffer and
allowed to incubate for 5-10 min. The same cell was then stimulated again with insulin in the presence of the chemical added.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cells evoked a rise in [Ca2+]i
(18). Our initial experiments were to further characterize this change
in [Ca2+]i at single cells. As shown in Fig.
1, application of 100 nM
insulin, but not buffer solution, results in increased [Ca2+]i as monitored by fluo-4 fluorescence. Fig.
1C illustrates further analysis of the images shown in Fig.
1 (A and B) as a plot of relative fluorescence
intensity (F1/F0) within the cell as a function
of time. Insulin induced increases in [Ca2+]i
were observed in 37 of 85 cells tested. All cells that were included in
this sampling had first responded with a [Ca2+]i
rise after tolbutamide stimulation. The cells that responded to insulin
displayed a variety of temporal patterns of
[Ca2+]i changes (Fig.
2). Of the 37 cells that responded to insulin, 9 (24%) exhibited biphasic or oscillatory response similar to
that in Fig. 1C or 2D, 9 cells (24%) showed a
transient peak response (Fig. 2A), 14 cells (38%) generated
an elevated plateau of [Ca2+]i that lasted more
than one minute after stimulation (Fig. 2B), and 5 cells
(14%) had a slow increase of [Ca2+]i that did
not peak or plateau after 2 min (Fig. 2C). The maximal
[Ca2+]i increase induced by insulin was
significantly smaller than that typically induced by a depolarizing
stimuli, 200 µM tolbutamide (Fig. 2, D and
E), and occurred with a much slower onset than that observed
with tolbutamide. The latency of responses to insulin was 12 ± 10 s, whereas that for tolbutamide was 1.5 ± 1 s. The
heterogeneity of temporal pattern is similar to that reported
previously for single cell studies of [Ca2+]i
changes induced by glucose in
-cells (27).

View larger version (30K):
[in a new window]
Fig. 1.
[Ca2+]i changes in
response to insulin stimulation. Confocal images were collected at
1 Hz using the fluorescent Ca2+ indicator, fluo-4, and
ratioed against the initial image in the series as described in text.
Image series are control stimulation with KRB (A) and
stimulation with 100 nM insulin for the same cell
(B). Stimulant was applied from 22 to 52 s. The ratio
value is indicated on the scale bar. The number
in each image indicates the time in seconds that the image was
collected. Note intracellular intensity increase at 38 s and the
much greater intensity increase in the cell interior in B. C, time course of changes in [Ca2+]i
in response to insulin stimulation (red line) and control
(blue line) for the cell above. Relative fluorescence
intensity (F1/F0) was
obtained by drawing a ROI around the entire cell and applying the ROI
to the entire series. The bar underneath the
traces indicates the application of 100 nM
insulin. D, comparison of [Ca2+]i
increases in the interior region (red line) and the edge of
the cell (blue line). The ROIs are indicated in the image,
where the region inside the red circle is used as the
interior region and the region between the concentric white
circles is used as the edge region.

View larger version (19K):
[in a new window]
Fig. 2.
Different patterns for the time course of
Ca2+ response to insulin stimulation as monitored by fluo-4
fluorescence. Images were acquired and analyzed as described in
the legend to Fig. 1. A, example of a cell with transient
peak response because of insulin stimulation. B, example of
a cell with plateau of [Ca2+]i increase in
response to insulin. C, example of cell with a slow increase
in [Ca2+]i after insulin stimulation.
D, comparison of responses induced by insulin and
tolbutamide from a cell that exhibited an oscillatory response to
insulin. E, comparison of maximal increase caused by
application of 200 µM tolbutamide for 5 s compared
to application of 100 nM insulin at same cells.
Bars in A-D indicate the application of
stimulant to the cell. A solid bar is for application of 100 nM insulin, and a dashed bar is for 200 µM tolbutamide. Control in A-C is
application of KRB to the cell for the same time as the insulin. 5 min
was allowed between stimulations at a cell.

View larger version (13K):
[in a new window]
Fig. 3.
Effects of thapsigargin on insulin-stimulated
insulin secretion and [Ca2+]i changes.
A, amperometric detection of 5-HT exocytosis from single
-cell upon stimulation with 100 nM insulin in the
absence of thapsigargin. B, amperometric detection of 5-HT
exocytosis from same cell as in A after 5 min of incubation
with 1 µM thapsigargin. C, typical insulin
induced [Ca2+]i traces of a cell in the absence
of thapsigargin (trace 1) and a cell that had been incubated
with 1 µM thapsigargin for 5 min (trace 2)
before stimulation. Bars under traces indicate
application of stimulant. Fluorescent data were collected and plotted
as described in the legends to Figs. 1 and 2.

View larger version (32K):
[in a new window]
Fig. 4.
Summary of the effect of experimental
manipulations on insulin-stimulated exocytosis (A) and
[Ca2+]i increases
(B). A, for insulin-stimulated
exocytosis, secretion was quantified as the number of exocytosis events
detected. Control bars (shaded) represent average
number of spikes detected before addition of drugs.
Experiment bars (hatched) represent average
number of spikes detected after addition of drugs. Statistically
significant difference between control and experimental bars is
indicated by an asterisk. The number of cells used for each
experiment is indicated over the bars. B,
[Ca2+]i increases were plotted as the maximal
percentage of increase over the basal level. The number of cells for
each condition is given over the bars. Only cells with an increase in
[Ca2+]i were used in averaging. All controls are
measurements in the absence of drugs except the control for U73122 is
in the presence of U73343, a structural analog of U73122. Statistically
significant difference between the control and the experimental bars is
indicated by an asterisk. In all cases, 100 nM
insulin was applied for 30 s. The following concentrations of
inhibitors were used: 20 µM nifedipine, 1 µM thapsigargin, 100 nM wortmannin, 10 µM U73122, 10 µM U73343, and 2 µM bisindolylmaleimide I. Statistical significance of
differences from control was p < 0.01 (asterisk).
-cells. The 5-HT method
was used instead of direct detection of insulin at a modified electrode
(23) because of the relative simplicity of this approach, especially
for autocrine studies. The validity of the 5-HT method has been
established by previous studies that demonstrated: 1) detection of
exocytosis with a variety of insulin secretogogues (24, 28, 29); 2)
that insulin and 5-HT are released exclusively from the same vesicles
(30); and 3) that direct detection of insulin and detection of 5-HT
give comparable results for insulin stimulation (18). As seen in Fig.
3A, application of 100 nM insulin to a single,
isolated
-cell results in detection of a series of current spikes at
the microelectrode indicative of exocytosis and subsequent detection of
packets of 5-HT diffusing to the electrode (24, 28, 29). Incubation of
cells with 1 µM thapsigargin completely abolished
insulin-induced exocytosis in all cells tested (n = 4;
Figs. 3B and 4A). In addition, insulin-stimulated insulin
secretion, measured as number of exocytosis events detected per
stimulation per cell, was not significantly affected by removal of
extracellular Ca2+ or by treatment with 20 µM
nifedipine (Fig. 4A). The results from the thapsigargin
treatment suggest an important role for Ca2+ released from
the ER in evoking secretion. In addition, the Ca2+-free and
nifedipine results indicate a minor, if any, role for extracellular
Ca2+ entering the cell in insulin activation of exocytosis.
-cells is mediated by
-cell insulin receptors (18). Insulin receptor substrates are
intimately coupled to the insulin receptor and hence the insulin
signaling pathway (31). To investigate the potential involvement of
IRS-1 in autocrine activation of
-cell secretion, we measured
insulin-stimulated insulin secretion and [Ca2+]i
changes in wild-type
TC3 cells (IRS-1 +/
) and IRS-1 knockout cells
(IRS-1
/
) as illustrated in Fig. 5.
We observed that much like primary
-cells, wild-type cells exhibited
insulin-induced exocytosis and [Ca2+]i changes.
Wild-type cells stimulated with 100 nM insulin evoked
detectable exocytosis in 16 of 33 cells attempted. In the IRS-1
knockout cells, no secretory activity was detected upon application of
100 nM insulin (25 of 25 cells) (Fig. 5C), even though these same cells exhibited secretion from tolbutamide
stimulation (Fig. 5C). Insulin-induced increases in
[Ca2+]i were observed in 7 of 16 wild-type cells.
The various patterns of [Ca2+]i increase seen
with primary
-cells were also seen with the wild-type cells. No
increase in [Ca2+]i was observed for IRS-1
knockout cells (13 of 13 cells) following insulin stimulation, but all
the cells used for insulin stimulation showed a
[Ca2+]i increase following 200 µM
tolbutamide stimulation (Fig. 5A). To summarize, in
wild-type
TC3 cells, insulin evoked exocytosis and
[Ca2+]i changes with a similar frequency and
magnitude to that observed in primary cells; however, in the IRS-1
knockout
TC3 cells, insulin did not evoke either
[Ca2+]i changes or exocytosis. These results
illustrate a critical role for IRS-1 in mediating the autocrine
[Ca2+]i changes and insulin secretion.

View larger version (20K):
[in a new window]
Fig. 5.
Effect of IRS-1 on insulin-stimulated insulin
secretion and [Ca2+]i changes in
TC3 cells. A,
[Ca2+]i images before and after stimulation.
Panel 1,
TC3 IRS-1 +/
(control) cell stimulated with
100 nM insulin; panel 2, IRS-1
/
cell
stimulated with 100 nM insulin; panel 3, the
same IRS-1
/
cell stimulated with 200 µM tolbutamide.
B, typical [Ca2+]i traces of a
TC3
wild-type cell (pink line) and IRS-1 knockout cell
(blue line). The bar underneath traces indicates
the application of 100 nM insulin. C, detection
of insulin-stimulated exocytosis in IRS-1 +/
(control) and IRS-1
/
TC3 cells. Detection of accumulated 5-HT secretion from
TC3
IRS-1 +/
cell stimulated with 100 nM insulin (trace
1), IRS-1-/- cell stimulated with 100 nM
insulin (trace 2), and IRS-1
/
cell stimulated with 200 µM tolbutamide (trace 3). Data in traces
2 and 3 are from the same cell. Bars under
current traces indicate application of stimulant. Ca2+ data
and images were prepared as for Fig. 1.
-cell, we investigated the
role of PI3-K in insulin-stimulated secretion and
[Ca2+]i changes in primary
-cells. Following
repetitive stimulation with 100 nM insulin to ensure that a
cell responded to insulin,
-cells were incubated with 100 nM wortmannin, a potent inhibitor of PI3-K, for 5 min. As
shown in Fig. 4A, wortmannin completely abolished exocytosis
from the
-cells, suggesting the requirement of PI3-K activation in
the insulin-stimulated insulin secretion pathway. The requirement of
PI3-K activation was also investigated for insulin-stimulated
[Ca2+]i changes. In the presence of 100 nM wortmannin, the insulin-induced Ca2+
response was significantly reduced (Fig. 4B).
(32, 33) and lead to
release of Ca2+ from inositol 1,4,5-trisphosphate-sensitive
Ca2+ stores. The effect of PLC activation on
insulin-stimulated insulin secretion was investigated by using the PLC
inhibitor U73122. As shown in Fig. 4A, in the presence of
the inhibitor, secretion was reduced to 82% of control; however, the
difference was not statistically significant. In the calcium
measurement, we used the structural analog of U73122, U73343, which
does not inhibit PLC; as a control. No difference between the effect of
U73122 and U73343 control was observed (Fig. 4B). In a
positive control, treatment with U73122 completely abolished the
secretory and Ca2+ response evoked by carbachol
stimulation, which is known to release Ca2+ through the
PLC-inositol 1,4,5-trisphosphate pathway. These data suggest that PLC
is not involved in the insulin-stimulated exocytosis signaling pathways.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cell insulin receptors play a role in
normal regulation of insulin secretion provides a potential direct link
between impaired insulin secretion and insulin resistance in type 2 diabetes (18, 20, 34, 35). Investigation of the signal transduction
mechanisms by which insulin exerts the stimulatory effect on insulin
secretion from the
-cell is therefore essential. Our data have shown
that insulin-stimulated insulin secretion is mediated by functional
insulin receptors (18), IRS-1, and PI3-K activation. Activation of
these substrates by insulin in
-cells has previously been reported
(16, 19), and our results illustrate that these effects are directly
linked to insulin secretion and increases in
[Ca2+]i.
-cell line
TC6-F7 inhibits
the uptake of Ca2+ into ER, possibly by inhibition of the
SERCA pump (19). The slow time course of the insulin-induced
[Ca2+]i changes is consistent with a mechanism
involving inhibition of the SERCA pump; however, further experiments
would be needed to establish this link.
-cells is
PKC. PKC can be activated by Ca2+ (38), and its activation
can elicit exocytosis in
-cells independent of entry of
Ca2+ from the extracellular environment (39). Our data
would support the hypothesis that IRS-1/PI3-K-mediated increases in
[Ca2+]i are necessary for insulin-evoked
exocytosis and that the [Ca2+]i changes and
secretion are linked at least by PKC, if not at other points in the
regulated exocytosis pathway. An interesting point in the link between
insulin-stimulated [Ca2+]i changes and exocytosis
is the observation that [Ca2+]i changes were
generally prolonged, typically lasting more than a minute after a 30-s
stimulation, but the secretory activity that we detected usually
occurred during a 30-s stimulation. This differential time course
suggests that other factors are necessary for secretion in the presence
of elevated [Ca2+]i. Such factors would
presumably be normally provided by glucose metabolism.
-cells.
-cell based on the data presented here.
Autocrine activation of insulin secretion in the
-cell is mediated
by activation of IRS-1 and PI3-K. PI3-K or its phosphatidylinositol products may be involved, with Ca2+, in direct activation
of the exocytosis machinery of the cell. IRS-1/PI3-K also evokes
release of Ca2+ from the ER by an as yet unknown mechanism.
The Ca2+ may be directly involved in activating exocytosis;
however, our data favor a requirement for PKC activation. Although our
results have emphasized autocrine activation of an insulin
receptor/IRS-1 pathway, previous investigations have demonstrated a
significant role for IRS-2 activation as well. Increased insulin
biosynthesis may be mediated by autocrine activation of IRS-2 (16). In
addition, mice with IRS-2 gene knockouts show defects in islet
development (45) and IRS-2 in
-cells may mediate IGF-1 receptor
effects on
-cell development and peripheral insulin signaling
(46).

View larger version (21K):
[in a new window]
Fig. 6.
Summary of insulin signaling pathway involved
in autocrine activation of secretion in pancreatic
-cell. Solid lines indicate
established effects or interactions, whereas dashed lines indicate
events with an unclear mechanism. Insulin applied exogenously or
released from secretory granules (SG) binds the insulin
receptor (IR), which activates IRS-1/PI3-K leading to
release of intracellular Ca2+ from the ER by an unknown
mechanism. Increased [Ca2+]i leads to insulin
secretion mediated by PKC. The possibility also exists for a more
direct involvement of PI3-K in activating exocytosis.
-cell. These
mechanisms are presumably activated by insulin released during normal
glucose stimulation in vivo. The importance of these effects
for normal glucose homeostasis has been demonstrated by the glucose
intolerance and reduction of first phase glucose-stimulated insulin
secretion in mice lacking the
-cell insulin receptor (20) and
impaired insulin secretion associated with IRS-1 polymorphisms (21). Further studies are needed to understand the linkage between effects regulated by glucose versus insulin and possible
interactions of insulin with metabolism in the
-cell. Defects in any
of the components of the insulin signaling pathway could be involved in
impaired insulin secretion and insulin resistance seen in diabetes; however, the actual role of autocrine regulation in diabetes remains to
be determined.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Schuit, F. C.,
Derde, M. P.,
and Pipeleers, D. G.
(1989)
Diabetologia
32,
207-212
2.
Norman, A. W.,
and Litwack, G.
(1997)
Hormones
, 2nd Ed.
, pp. 193-227, Academic Press, San Diego, CA
3.
Moens, K.,
Himberg, H.,
Flamez, D.,
Huypens, P.,
Quartier, E.,
Ling, Z.,
Pipeleers, D.,
Gremlich, S.,
Thorens, B.,
and Schuit, F.
(1996)
Diabetes
45,
257-261
4.
Verspohl, E. J.,
and Ammon, H. P. T.
(1980)
J. Clin. Invest.
65,
1230-1237
5.
Gazzano, H.,
Halban, P.,
Prentki, M.,
Ballotti, R.,
Brandenburg, D.,
Fehlmann, M.,
and Van Obberghen, E.
(1985)
Biochem. J.
226,
867-872
6.
Rothenberg, P. L.,
Willison, L. D.,
Simon, J.,
and Wolf, B. A.
(1995)
Diabetes
44,
802-809
7.
Harbeck, M. C.,
Louie, D. C.,
Howland, J.,
Wolf, B. A.,
and Rothenberg, P. L.
(1996)
Diabetes
45,
711-717
8.
Velloso, L. A.,
Carneiro, E. M.,
Crepaldi, S. C.,
Boschero, A. C.,
and Saad, M. J. A.
(1995)
FEBS Lett.
377,
353-357
9.
Sun, X. J.,
Pons, S.,
Wang, L. M.,
Zhang, Y. T.,
Yenush, L.,
Burks, D.,
Myers, M. G.,
Glasheen, E.,
Copeland, N. G.,
Jenkins, N. A.,
Pierce, J. H.,
and White, M. F.
(1997)
Mol. Endocrinol.
11,
251-262
10.
Alter, C. A.,
and Wolf, B. A.
(1995)
Biochem. Biophys. Res. Commun.
208,
190-197
11.
Gao, Z.-Y.,
Konrad, R. J.,
Collins, H.,
Matschinsky, F. M.,
Rothenberg, P. L.,
and Wolf, B. A.
(1996)
Diabetes
45,
854-862
12.
Holst, L. S.,
Mulder, H.,
Manganiello, V.,
Sundler, F.,
Ahren, B.,
Holm, C.,
and Degerman, E.
(1998)
Biochem. Biophys. Res. Commun.
250,
181-186
13.
Patel, Y. C.,
Amherdt, M.,
and Orci, L.
(1982)
Science
217,
1155-1156
14.
Xu, G.,
Marshall, C. A.,
Lin, T.-A.,
Kwon, G.,
Munivenkatappa, R. B.,
Hill, J. R.,
Lawrence, J. C., Jr.,
and McDaniel, M. L.
(1998)
J. Biol. Chem.
273,
4485-4491
15.
Xu, G.,
and Rothenberg, P. L.
(1998)
Diabetes
47,
1243-1252
16.
Leibiger, I. B.,
Leibiger, B.,
Moede, T.,
and Berggren, P.-O.
(1998)
Mol. Cell
1,
933-938
17.
Kulkarni, R. N.,
Winnay, J. N.,
Brüning, J. C.,
and Hanahan, D.
(1998)
Diabetes
47,
A57
18.
Aspinwall, C. A.,
Lakey, J. R. T.,
and Kennedy, R. T.
(1999)
J. Biol. Chem.
274,
6360-6365
19.
Xu, G. G.,
Gao, Z. Y.,
Borge, P. D.,
and Wolf, B. A.
(1999)
J. Biol. Chem.
274,
18067-18074
20.
Kulkarni, R. N.,
Brüning, J. C.,
Winnay, J. N.,
Postic, C.,
Magnuson, M. A.,
and Kahn, C. R.
(1999)
Cell
96,
329-339
21.
Porzio, O.,
Federici, M.,
Hribal, M. L.,
Lauro, D.,
Accili, D.,
Lauro, R.,
Borboni, P.,
and Sesti, G.
(1999)
J. Clin. Invest.
104,
357-364
22.
Efrat, S.,
Linde, S.,
Kofod, H.,
Spector, D.,
Delannoy, M.,
Grant, S.,
Hanahan, D.,
and Baekkeskov, S.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
9037-9341
23.
Huang, L.,
Shen, H.,
Atkinson, M. A.,
and Kennedy, R. T.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9608-9612
24.
Aspinwall, C. A.,
Brooks, S. A.,
Kennedy, R. T.,
and Lakey, J. R. T.
(1997)
J. Biol. Chem.
272,
31308-31314
25.
Guerineau, N. C.,
Bonnefont, X.,
Stoeckel, L.,
and Mollard, P.
(1998)
J. Biol. Chem.
273,
10389-10395
26.
Chanson, M.,
Mollard, P.,
Meda, P.,
Suter, S.,
and Jongsma, H. J.
(1999)
J. Biol. Chem.
274,
282-287
27.
Theler, J.-M.,
Mollard, P.,
Guerineau, N.,
Vacher, P.,
Pralong, W. F.,
Schlegel, W.,
and Wollheim, W. B.
(1992)
J. Biol. Chem.
267,
18110-18117
28.
Smith, P. A.,
Duchen, M. R.,
and Ashcroft, F. M.
(1995)
Pfluegers Arch. Eur. J. Physiol.
430,
808-818
29.
Zhou, Z.,
and Misler, S.
(1996)
J. Biol. Chem.
270,
3498-3505
30.
Aspinwall, C. A.,
Huang, L.,
Lakey, J. R. T.,
and Kennedy, R. T.
(1999)
Anal. Chem.
71,
5551-5556
31.
White, M. F.
(1997)
Diabetologia
40,
S2-S17
32.
Bae, Y. S.,
Cantley, L. G.,
Chen, C.-S.,
Kim, S.-R.,
Kwon, K.-S.,
and Rhee, S. G.
(1998)
J. Biol. Chem.
273,
4465-4469
33.
Falasca, M.,
Logan, S. K.,
Lehto, V. P.,
Baccante, G.,
Lemmon, M. A.,
and Schlessinger, J.
(1998)
EMBO J.
17,
414-422
34.
Rutter, G. A.
(1999)
Curr. Biol.
9,
443-445
35.
Taylor, S. I.
(1999)
Cell
97,
9-12
36.
Zawalich, W. S.,
Zawalich, K. C.,
and Kelley, G. G.
(1995)
Endocrinology
136,
4903-4909
37.
Algenstaedt, P.,
Antonetti, D. A.,
Yaffe, M. B.,
and Kahn, C. R.
(1997)
J. Biol. Chem.
272,
23696-23702
38.
Ashcroft, S. J.
(1994)
Diabetologia
37 (Suppl. 2),
S21-S29
39.
Eliasson, L,
Renstrom, E,
Ammala, C,
Berggren, P. O.,
Bertorello, A. M.,
Bokvist, K.,
Chibalin, A.,
Deeney, J. T.,
Flatt, P. R.,
Gabel, J.,
Gromada, J.,
Larsson, O.,
Lindstrom, P.,
Rhodes, C. J.,
and Rorsman, P.
(1996)
Science
271,
813-5
40.
De Camilli, P.,
Scott, D. E.,
McPherson, P. S.,
and Novick, P.
(1996)
Science
271,
1533-1539
41.
Shepherd, P. R.,
Reaves, B. J.,
and Davidson, H. W.
(1996)
Trends Cell Biol.
6,
92-97
42.
Cheatham, B.,
Vlahos, C. J.,
Cheatham, L.,
Wang, L.,
Blenis, J.,
and Kahn, C. R.
(1994)
Mol. Cell. Biol.
14,
4902-4911
43.
Chasserot-Golaz, S.,
Hubert, P.,
Thierse, D.,
Dirrig, S.,
Vlahos, C. J.,
Aunis, D.,
and Bader, M. F.
(1998)
J. Neurochem.
70,
2347-2356
44.
Schiavo, G., GU, Q. M.,
Pretwich, G. D.,
Sollner, T. H.,
and Rothman, J. E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13327-13332
45.
Withers, D. J.,
Gutierrez, J. S.,
Towery, H.,
Burks, D. J.,
Ren, J.-M.,
Previs, S.,
Zhang, Y.,
Bernal, D.,
Pons, S.,
Shulman, G. I.,
Bonner-Weir, S.,
and White, M. F.
(1998)
Nature
391,
900-904
46.
Withers, D. J.,
Burks, D. J.,
Towery, H.,
Altamuro, S. L.,
Flint, C. L.,
and White, M. F.
(1999)
Nat. Genet.
23,
32-40
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. Yu, P.-O. Berggren, and C. J. Barker An Autocrine Insulin Feedback Loop Maintains Pancreatic {beta}-Cell 3-Phosphorylated Inositol Lipids Mol. Endocrinol., November 1, 2007; 21(11): 2775 - 2784. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. I. Hagren and A. Tengholm Glucose and Insulin Synergistically Activate Phosphatidylinositol 3-Kinase to Trigger Oscillations of Phosphatidylinositol 3,4,5-Trisphosphate in beta-Cells J. Biol. Chem., December 22, 2006; 281(51): 39121 - 39127. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Johnson, E. Bernal-Mizrachi, E. U. Alejandro, Z. Han, T. B. Kalynyak, H. Li, J. L. Beith, J. Gross, G. L. Warnock, R. R. Townsend, et al. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome PNAS, December 19, 2006; 103(51): 19575 - 19580. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-F. Zhao, D. J Keating, M. Hernandez, D. D. Feng, Y. Zhu, and C. Chen Long-term inhibition of protein tyrosine kinase impairs electrophysiologic activity and a rapid component of exocytosis in pancreatic {beta}-cells J. Mol. Endocrinol., August 1, 2005; 35(1): 49 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Hennige, U. Ozcan, T. Okada, U. S. Jhala, M. Schubert, M. F. White, and R. N. Kulkarni Alterations in growth and apoptosis of insulin receptor substrate-1-deficient {beta}-cells Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E337 - E346. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aquila, M. Gentile, E. Middea, S. Catalano, and S. Ando Autocrine Regulation of Insulin Secretion in Human Ejaculated Spermatozoa Endocrinology, February 1, 2005; 146(2): 552 - 557. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Katzman, M. A. Messerli, D. T. Barry, A. Grossman, T. Harel, J. D. Wikstrom, B. E. Corkey, P. J. S. Smith, and O. S. Shirihai Mitochondrial metabolism reveals a functional architecture in intact islets of Langerhans from normal and diabetic Psammomys obesus Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1090 - E1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Nunemaker, M. Zhang, and L. S. Satin Insulin Feedback Alters Mitochondrial Activity Through an ATP-sensitive K+ Channel-Dependent Pathway in Mouse Islets and {beta}-Cells Diabetes, July 1, 2004; 53(7): 1765 - 1772. [Abstract] |